CG Oncology (CGON) Return on Capital Employed (2024 - 2026)
CG Oncology (CGON) posted Return on Capital Employed of 23.16% for Q1 2026, up 11.39% on a QoQ basis from 26.14% in Q4 2025, and down 446.0% year-over-year from 6.69% in Q1 2025.
CG Oncology (CGON) Return on Capital Employed (2024 - 2026) Analysis & Trends
CG Oncology's Return on Capital Employed history runs 3 years deep, the most recent figure standing at 23.16% for Q1 2026.
- Quarterly Return on Capital Employed fell 446.0% year-over-year to 23.16% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 23.16% (down 446.0% YoY) and the FY2025 annual result came in at 25.7%, down 53.0% from the prior year.
- Return on Capital Employed was 23.16% for Q1 2026 at CG Oncology, up from 26.14% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 14.6% in Q2 2024 and bottomed at 26.29% in Q3 2025.
- A 3-year average of 20.63% and a median of 18.7% in 2025 frame the typical range for Return on Capital Employed.
- Peak annual rise in Return on Capital Employed reached 71 bps in 2025, while the deepest fall reached 861 bps in 2025.
- CG Oncology's Return on Capital Employed stood at 18.14% in 2024, then tumbled by 44 bps to 26.14% in 2025, then grew by 11 bps to 23.16% in 2026.
- Business Quant data shows CGON's Return on Capital Employed at 23.16% in Q1 2026, 26.14% in Q4 2025, and 26.29% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | CG Oncology | 6.01 Bn | 6.01 Bn | -1.88 Mn | -23.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.16% |
| Dec 31, 2025 | -26.14% |
| Sep 30, 2025 | -26.29% |
| Jun 30, 2025 | -22.98% |
| Mar 31, 2025 | -18.70% |
| Dec 31, 2024 | -18.14% |
| Sep 30, 2024 | -17.68% |
| Jun 30, 2024 | -14.60% |
| Mar 31, 2024 | -17.98% |